A close look at BACE1 inhibitors for Alzheimer's disease treatment

B Das, R Yan - CNS drugs, 2019‏ - Springer
Abstract Alzheimer's disease (AD), the most common cause of age-dependent dementia, is
one of the most significant healthcare problems worldwide. Aggravating this situation, drugs …

Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies

Y Chen, AKY Fu, NY Ip - Pharmacology & therapeutics, 2019‏ - Elsevier
Abstract Alzheimer's disease (AD), the most prevalent neurodegenerative disease in the
elderly population, is characterized by progressive cognitive decline and pathological …

Depletion of acetate-producing bacteria from the gut microbiota facilitates cognitive impairment through the gut-brain neural mechanism in diabetic mice

H Zheng, P Xu, Q Jiang, Q Xu, Y Zheng, J Yan, H Ji… - Microbiome, 2021‏ - Springer
Background Modification of the gut microbiota has been reported to reduce the incidence of
type 1 diabetes mellitus (T1D). We hypothesized that the gut microbiota shifts might also …

[HTML][HTML] Amyloid beta and tau cooperate to cause reversible behavioral and transcriptional deficits in a model of Alzheimer's disease

EK Pickett, AG Herrmann, J McQueen, K Abt, O Dando… - Cell reports, 2019‏ - cell.com
A key knowledge gap blocking development of effective therapeutics for Alzheimer's disease
(AD) is the lack of understanding of how amyloid beta (Aβ) peptide and pathological forms of …

The beta amyloid dysfunction (BAD) hypothesis for Alzheimer's disease

H Hillen - Frontiers in Neuroscience, 2019‏ - frontiersin.org
Beta amyloid, Aβ 1–42, originally named as Amyloid A4 protein, is one of the most
investigated peptides in neuroscience and has attracted substantial interest since its …

Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer's disease

AM Eteleeb, BC Novotny, CS Tarraga, C Sohn… - PLoS …, 2024‏ - journals.plos.org
Unbiased data-driven omic approaches are revealing the molecular heterogeneity of
Alzheimer disease. Here, we used machine learning approaches to integrate high …

[HTML][HTML] Neuroprotective effects of chronic resveratrol treatment and exercise training in the 3xTg-AD mouse model of Alzheimer's disease

TL Broderick, S Rasool, R Li, Y Zhang… - International journal of …, 2020‏ - mdpi.com
To date, there is no cure or effective treatment for Alzheimer's disease (AD), a chronic
neurodegenerative condition that affects memory, language, and behavior. AD is …

[HTML][HTML] CYP46A1 activation by efavirenz leads to behavioral improvement without significant changes in amyloid plaque load in the brain of 5XFAD mice

AM Petrov, M Lam, N Mast, J Moon, Y Li, E Maxfield… - …, 2019‏ - Elsevier
Efavirenz, the FDA-approved anti-retroviral medication, is evaluated in the clinical trial in
patients with mild cognitive impairment or early dementia due to Alzheimer's disease …

[HTML][HTML] Aβ and tau interact with metal ions, lipid membranes and peptide-based amyloid inhibitors: are these common features relevant in Alzheimer's disease?

G Di Natale, G Sabatino, MFM Sciacca, R Tosto… - Molecules, 2022‏ - mdpi.com
In the last two decades, the amyloid hypothesis, ie, the abnormal accumulation of toxic Aβ
assemblies in the brain, has been considered the mainstream concept sustaining research …

microRNAs as early biomarkers of Alzheimer's disease: A synaptic perspective

D Siedlecki-Wullich, AJ Miñano-Molina… - Cells, 2021‏ - mdpi.com
Pathogenic processes underlying Alzheimer's disease (AD) affect synaptic function from
initial asymptomatic stages, long time before the onset of cognitive decline and …